4-ALLYL-2-METHOXYPHENYL [1-(4-CHLOROBENZOYL)-5-METHOXY-2-METHYL-1H-INDOL-3-YL]ACETATE


Molecule Category	Free-form
Source	Gaulton A, Kale N, van Westen GJ, Bellis LJ, Bento AP, Davies M, Hersey A, Papadatos G, Forster M, Wege P, Overington JP. A large-scale crop protection bioassay data set. Sci Data. 2015 Jul 7;2:150032. Read more ...


Active Pharmaceutical Ingredients Bioactive chemicals	Exact Similarity SubStructure	Threshold (%) >= 70

Structure


InChI Key	BYMQVRPNPVAVEL-UHFFFAOYSA-N
Smiles	COc1ccc2c(c1)c(CC(=O)Oc3ccc(CC=C)cc3OC)c(C)n2C(=O)c4ccc(Cl)cc4
InChI	InChI=1S/C29H26ClNO5/c1-5-6-19-7-14-26(27(15-19)35-4)36-28(32)17-23-18(2)31(25-13-12-22(34-3)16-24(23)25)29(33)20-8-10-21(30)11-9-20/h5,7-16H,1,6,17H2,2-4H3

Physicochemical Descriptors

Property Name	Value
Molecular Formula	C29H26ClNO5
Molecular Weight	503.97
AlogP	7.03
Hydrogen Bond Acceptor	5.0
Hydrogen Bond Donor	0.0
Number of Rotational Bond	9.0
Polar Surface Area	66.76
Molecular species	None
Aromatic Rings	4.0
Heavy Atoms	36.0

Assay Description	Organism	Bioactivity
Antiulcerogenic activity in fasted Rattus norvegicus Sprague-Dawley (rat) stomach assessed as ulcer index at 67.6 mg/kg, po after 8 hr (Rvb = 0.23 +/- 0.09)	Rattus norvegicus	0.93
Analgesic activity in Rattus norvegicus Sprague-Dawley (rat) assessed as inhibition of acetic acid-induced abdominal writhing at 14.08 mg/kg, po measured for 20 min relative to vehicle-treated control	Rattus norvegicus	84.75 %
Anti-inflammatory activity in Rattus norvegicus Sprague-Dawley (rat) assessed as increase in carrageenan-induced paw edema at 16.9 mg/kg, po measured at 4 hr by plethysmometer (Rvb = 81.58 +/- 0.63 %)	Rattus norvegicus	45.39 %
Anti-inflammatory activity in Rattus norvegicus Sprague-Dawley (rat) assessed as increase in carrageenan-induced paw edema at 16.9 mg/kg, po measured at 2 hr by plethysmometer (Rvb = 64.73 +/- 0.72 %)	Rattus norvegicus	44.33 %

Cross References

Resources	Reference
ChEMBL	CHEMBL2236585
PubChem	60167991

CONTENTS


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).